There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kadmon Holdings (KDMN) and CytoDyn Inc (CYDY) with bullish sentiments.
Kadmon Holdings (KDMN)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Kadmon Holdings today and set a price target of $25. The company’s shares closed yesterday at $1.74, close to its 52-week low of $1.64.
According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.0% and a 41.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and ACADIA Pharmaceuticals Inc.
Kadmon Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $25.
See today’s analyst top recommended stocks >>
CytoDyn Inc (CYDY)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on CytoDyn Inc today and set a price target of $1.50. The company’s shares closed yesterday at $0.48.
Chen commented:
“We note that the only product currently in use for PrEP is Truvada, which is a daily pill. However, many patients cannot adhere to daily oral antiretroviral therapy drugs as PrEP; therefore, once-weekly leronlimab as PrEP could be a viable option to curtail the epidemic, considering that individuals deficient for the CCR5 co-receptor are nearly completely resistant to sexual transmission of HIV. Importantly, potential use of leronlimab as PrEP could provide an additional label expansion opportunity on top of monotherapy, in our view, if leronlimab is approved as a combination therapy first. In the wake of this update, we reiterate our Buy rating and $1.50 price target.”
According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -25.6% and a 34.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, Aslan Pharmaceuticals Ltd, and Seelos Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CytoDyn Inc with a $1.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
